selectION, Inc. has shared encouraging outcomes from its initial human Phase 1b study concerning its primary drug, si-544, targeted at individuals with atopic dermatitis.

This paper reported an innovative computational approach that successfully achieved the design and prediction of macrocyclic oligoamides composed of alpha, beta, gamma, and other non-natural amino acid backbone chemical structures.

AriBio Granted EMA Approval for Phase 3 Trials of AR1001 in Alzheimer’s Treatment (POLARIS-AD).

A clinical trial default approval is a system where applicants can proceed with drug trials as planned if the review agency does not reject or question the submission within a set period.

Ractigen Therapeutics has received FDA clearance for RAG-01, a pioneering saRNA treatment for NMIBC that does not respond to BCG.

April 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

U.S. FDA Sanctions Single-Dose Gene Treatment BEQVEZ™ (fidanacogene elaparvovec-dzkt) by Pfizer for Adult Hemophilia B Patients.

A rare disease, also known as an "orphan disease," refers to diseases with relatively low prevalence rates.

Advanced gastrointestinal cancer patients continue to test dosages with the novel T-cell engager, CDH17 X CD3 cabotamig (ARB202).

April 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Cidara Therapeutics regains worldwide control for developing and marketing CD388, also launches a $240 million private funding initiative.

On March 27th, Japan's Sosei Group Corporation announced that their board members and executives were reelected during the 34th Annual General Meeting and subsequent board meeting in Tokyo.